FAEGRE DRINKER BIDDLE & REATH LLP lobbying for TEVA PHARMACEUTICALS USA, INC.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 16, 2026

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Lobbyists on this filing 2

MEGAN SUSSMAN HERBER

Previously held: Legislative Director/Senior Legislative Assistant/Legislative Assistant, Rep. Doris Matsui (D-CA) 2014-2018
ELLIOT VICE

Previously held: Staff Assistant, Legislative Correspondent & Scheduler, Sen. Evan Bayh (D-IN) 2009-2010

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 3

Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Lobbying activity 2

Health Issues

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform.

Copyright/Patent/Trademark

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform.